Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
47 hedge funds and large institutions have $9.43M invested in Melinta Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 13 closing their positions.
5% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $1.22M
11% less funds holding
Funds holding: 53 → 47 (-6)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
47% less capital invested
Capital invested by funds: $17.8M → $9.43M (-$8.36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.22M |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$157K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$132K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$132K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$65.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$826K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$607K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$516K |
| 4 |
D.E. Shaw & Co
New York
|
-$357K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$205K |
MLNT Hedge Fund Activity: Q3 2019 in Review
47 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q3 2019, worth a combined $9.43M — down 47% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of MLNT and 7 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.22M. The largest seller was Millennium Management, exiting entirely with an estimated $826K sold.
- 47 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q3 2019, down from 53 in Q2 2019.
- Funds reported $9.43M of Melinta Therapeutics, Inc. Common Stock stock for Q3 2019, down 47% quarter-over-quarter.
- 7 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q3 2019 and 13 closed out, a net change of -6 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q3 2019 was Renaissance Technologies, an estimated $1.22M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q3 2019 was Millennium Management, an estimated $826K sold.
Based on aggregated 13F filings for Q3 2019.